Jupiter Life Line Hospitals’ IPO to open on Sept. 6

Sets price band at ?695 to ?735 per Equity Share

Global health challenges can be resolved using digital technology: Dr Alain Labrique

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Elekta and IAEA partner to improve access to cancer care in underserved countries

Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden

European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ

KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population

Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales

Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

IBL Healthcare invests in KNISS Laboratories

KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.

Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators

Intuitive and Max Healthcare to launch TPO Centre for robotic-assisted surgery

Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery